Welcome to the e-CCO Library!

DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hart A., Li K., Gasink C., Jacobstein D., Brodmerkel C.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Hart A.
Genetic factors, Pharmacogenetics, Ustekinumab
Files: 1
DOP046: Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Berends1,2*, M. Löwenberg2, F. Baert3, R. Mathôt1, E. Clasquin2, C. Van Der Woude4, F. Hoentjen5, P. Bossuyt6, D. Franchimont7, T. Rispens8,9, A. De Vries9, S. Vermeire10, G. D'Haens2

Created: Thursday, 21 February 2019, 9:14 AM
DOP046: Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1 189 patients with Crohns disease: a multicentre cohort study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. Tanaka*1, N. Kamata2, A. Yamada3, K. Endo4, T. Fujii5, T. Yoshino6, 7, T. Sugaya8, Y. Yokoyama9, S. Bamba10, J. Umeno11, Y. Yanai12, M. Ishii13, T. Kawaguchi14, S. Shinzaki15, Y. Toya16, T. Kobayashi17, M. Nojima18, T. Hibi17

Created: Friday, 22 February 2019, 9:49 AM
DOP047: Early fibrostenosis in Crohn's disease is associated with multiple susceptibility loci on Immunochip analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Holvoet T.*1, Bossuyt P.2,3, Cleynen I.3, De Kock I.4, Hindryckx P.1, Vermeire S.3,5, Laukens D.1, De Vos M.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP047: Early fibrostenosis in Crohn’s Disease is associated with multiple susceptibility loci on Immunochip analysis
Year: 2017
Source: ECCO'17 Barcelona
Authors: Holvoet T.
Genetic factors, Fibrosis, Genetics
Files: 1
DOP047: Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Dreesen1*, G. D'Haens2, F. Baert3, B. Pariente4, Y. Bouhnik5, J. vander Woude6, J. Moreau7, D. Laharie8, S. Vermeire9,10, A. Gils1

Created: Thursday, 21 February 2019, 9:14 AM
DOP047: PYRAMID registry: an observational study of adalimumab in Crohns disease—results at year 7
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens1, W. Reinisch*2, J. Satsangi3, E. Loftus Jr4, R. Panaccione5, H. Read6, M. Heinrich7, J. Petersson6, A.M. Robinson6

Created: Friday, 22 February 2019, 9:49 AM
DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 7
Year: 2016
Source: ECCO'16 DOP
Authors: Reinisch W.
anti-TNF agents, Crohn's Disease
Files: 1
DOP048: Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome—post-hoc analyses from the PURSUIT programme
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J.-F. Colombel*1, W. Reinisch2, P. Gibson3, W. J. Sandborn4, B. Feagan5, S. Xu6, R. Strauss6, H. Zhang6, D. Tarabar7, Z. Hebzda8, P. Rutgeerts9, C. Marano6

Created: Friday, 22 February 2019, 9:49 AM
DOP048: PROFILE trial: predicting outcomes for Crohn's disease using a molecular biomarker
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lee J.1,2, Biasci D.1, Noor N.*1,2, McKinney E.1, Ahmad T.3,4, Lewis N.5, Hart A.6,7, Lyons P.1, Parkes M.1,2, Smith K.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP048: PROFILE trial: Predicting outcomes for Crohn’s Disease using a molecular biomarker
Year: 2017
Source: ECCO'17 Barcelona
Authors: Noor N.
Natural history, Genetics, T cell
Files: 1
DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Yarur1*, A. Bruss1, C. Fox1, P. Beniwal-Patel1, A. Patel1, B. Berens1, S. Naik2, D. Stein1

Created: Thursday, 21 February 2019, 9:14 AM
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Tarabar1*, K. El Jurdi2, O. Yvellez2, Z. Milenkovic1, S. Petrovic1, B. Subotic1, T.P. Brocic1, I. Brcerevic1, O. Latinovic3, D.T. Rubin2

Created: Thursday, 21 February 2019, 9:14 AM
DOP049: Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Probert*1, D. R. Gaya2, P. J. Hamlin3, P. Irving4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6

Created: Friday, 22 February 2019, 9:49 AM
DOP049: Inflammatory dyskinesis: defects of NF-κB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sellge G.*1, Papoutsopoulou S.2, Verdier J.1, Trautwein C.1, Bergey F.3, Burkitt M.4, Burkitt M.4, Sheibani R.5, Pierik M.6, Jonkers D.6, White M.2, Paszek P.2, Martins dos Santos V.3, Rosenstiel P.5, Müller W.2, Probert C.4 SysmedIBD Consortium2

Created: Wednesday, 20 February 2019, 10:36 AM